Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients

Paola Canzano, PhD,a,* Marta Brambilla, PhD,a,* Benedetta Porro, PhD,a Nicola Cosentino, MD, PhD,a Elena Tortorici, MD,b Stefano Vicini, MD,b Paolo Poggio, PhD,a Andrea Cascella, MD,b Martino F. Pengo, MD, PhD,b Fabrizio Veglia, PhD,a Susanna Fiorelli, PhD,a Alice Bonomi, PhD,a Viviana Cavalca, PhD,a Daniela Trabattoni, MD,a Daniele Andreini, MD, PhD,a, Emanuela Omodeo Salè, PhD,a Gianfranco Parati, MD,b Elena Tremoli, PhD,b,† Marina Camera, PhD,a,c,†

HIGHLIGHTS

- The cytokine storm present in COVID-19 patients induces, together with the imbalance of endothelial functions, a massive cell activation with production of tissue factor, mainly by platelets, granulocytes, and MVs.
- Plasma MV-associated thrombin generation is present in patients despite prophylactic anticoagulation.
- COVID-19 plasma, added to the blood of healthy subjects, induces platelet activation similar to what is observed in vivo. This effect is blunted by pre-incubation with tocilizumab, giving insights into the IL-6-mediated platelet activation that triggers the hypercoagulable state in COVID-19, suggesting the potential effectiveness of anti-IL-6 antibodies and antiplatelet drugs.
- Our data provide the bench-to-clinic rationale behind the ongoing clinical trial assessing the potential effectiveness of antiplatelet drugs and IL-6R antagonists in the treatment of COVID-19 patients.
The authors hypothesized that the cytokine storm described in COVID-19 patients may lead to consistent cell-based tissue factor (TF)-mediated activation of coagulation, procoagulant microvesicles (MVs) release, and massive platelet activation. COVID-19 patients have higher levels of TF-platelet, TF granulocytes, and TF MVs than healthy subjects and coronary artery disease patients. Plasma MV-associated thrombin generation is present in prothrombinanticoagulated patients. A sustained platelet activation in terms of P-selectin expression and platelet-leukocyte aggregate formation, and altered nitric oxide/prostacyclin synthesis are also observed. COVID-19 plasma, added to the blood of healthy subjects, induces platelet activation similar to that observed in vivo. This effect was blunted by pre-incubation with tocilizumab, aspirin, or a P2Y12 inhibitor. (J Am Coll Cardiol Basic Trans Science 2021;1:1-4 © 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)).

Summary

Since the outbreak of the coronavirus disease-2019 (COVID-19) pandemic, a growing amount of clinical data has documented how severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) may predispose patients to thrombotic disease, both in the venous and arterial vascular beds (1,2).

Patients with severe COVID-19 pneumonia experience hypoxemia, not only due to inflammatory alveolar involvement, but also to endothelial dysfunction together with a systemic cytokine storm response, which ultimately leads to micro- and macrothrombosis in the pulmonary vessels, as well as in other organs. Abnormal coagulation parameters, that is, a significant rise of D-dimer levels, prolonged prothrombin time, and low platelet counts, reflect the coagulopathy that correlates well with disease severity in COVID-19 patients (3). Interestingly, the severe thrombotic complications may develop despite standard pharmacological prophylaxis with heparin.

It has been well documented that inflammation due to viral and bacterial infections can lead to the systemic activation of coagulation (4). D-dimer, an independent predictor of poor prognosis in COVID-19, is a biomarker of this activation that is triggered by tissue factor (TF), the key activator of the blood coagulation cascade. D-dimer, however, does not identify per se the underlying molecular mechanisms and/or the dysfunctional cell population involved in its production.

Endothelial injury, a common feature of viral infection, can alter hemostasis directly or indirectly (5). Viral or bacterial infections and inflammatory stimuli can indeed induce TF expression, not only in endothelial, but also in circulating, monocytes and granulocytes. These cells upon activation also release microvesicles (MVs) into the bloodstream. Among the circulating MVs, those expressing phosphatidylserine (PS) and TF are defined as procoagulant MVs and globally contribute to the activation of the coagulation (6).

Severe imbalances of endothelial function during systemic infections with hyperinflammation can further alter hemostasis through the reduced production or action of mediators such as prostacyclin (PGI2) and nitric oxide (NO), pivotal in the control of platelet activation (7). Platelets participate in inflammation and thrombotic responses in many viral infections (8). The low platelet count often described in COVID-19 patients indeed suggests increased consumption due to a massive platelet activation and thrombus formation. It should be mentioned in this regard that activated platelets also express a functionally active TF (9). Thus, within the hemostatic process, platelets not only aggregate providing the negatively charged phospholipid bilayer for the
assembly of the coagulation factors, but they are able themselves to trigger the coagulation cascade.

Finally, the cytokine storm associated with severe COVID-19, which is considered a pathological underpinning for disease progression and multiorgan failure in these patients, is characterized by increased plasma concentrations of several cytokines including interleukin-6 (IL-6) (10). Preclinical studies seem to suggest the efficacy of anti-IL-6 receptor (IL-6R) blockade with tocilizumab (11,12). However, the effect of the cytokine release on platelet and endothelial activation in this clinical setting is almost completely unknown. Thus, whereas data are rapidly emerging about COVID-19-associated coagulopathy and thrombosis risk, there is little high-quality evidence to guide antithrombotic management.

On the basis of the findings collected so far, we hypothesized that the cytokine storm taking place in COVID-19 patients, deeply affecting endothelial functions, leads to consistent blood cell activation, resulting, not only in a generalized cell-based TF-mediated activation of blood coagulation and release of procoagulant MVs, but also in a massive platelet activation. Thus, we carried out this study to assess in COVID-19-associated coagulopathy and thrombosis risk, there is little high-quality evidence to guide antithrombotic management.

On the basis of the findings collected so far, we hypothesized that the cytokine storm taking place in COVID-19 patients, deeply affecting endothelial functions, leads to consistent blood cell activation, resulting, not only in a generalized cell-based TF-mediated activation of blood coagulation and release of procoagulant MVs, but also in a massive platelet activation. Thus, we carried out this study to assess in COVID-19 patients: 1) the level of TF expression among the circulating cells and MVs; 2) the residual plasma thrombin generation capacity despite heparin treatment; and 3) the extent of platelet and endothelial activation.

Finally, through an in vitro approach, we verified whether plasma from COVID-19 patients added to blood cells from healthy subjects (HS) induced platelet activation similar to what is observed in vivo. In this experimental setting, we also assessed whether IL-6R blockade or antiplatelet drugs reverted platelet activation.

**METHODS**

**PATIENT SELECTION.** This prospective study recruited 46 consecutive COVID-19 patients admitted to San Luca Hospital, Istituto Auxologico Italiano IRCCS, Milan, between April 1st and 30th, 2020. Patients with a positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) polymerase chain reaction test and requiring oxygen supplementation were included. Criteria for hospital admission were defined as those requiring inpatient care as a result of the severity of illness based on laboratory and radiological parameters, as well as clinical findings. Study patients were divided into 2 groups according to their oxygen supplementation: patients needing low-flow oxygen supplementation only (with nasal cannulae or Venturi mask, group 1) and patients needing mechanical ventilation (invasive or noninvasive, group 2). Following admission, all patients received supportive care in line with best international practice. In particular, hospitalized COVID-19 patients were treated with: 1) lopinavir/ritonavir or darunavir/cobicistat; 2) with/without hydroxychloroquine; 3) with/without antibiotic prophylaxis; or 4) with/without steroids. Moreover, hospitalized patients for COVID-19 received low-molecular-weight heparin (LMWH) thromboprophylaxis according to their body weight and renal function, unless contraindicated, as part of standard of care.

Biochemical variables, including inflammatory and thrombotic parameters (IL-6, C-reactive protein [CRP], lactate dehydrogenase [LDH], fibrinogen, D-dimer, procalcitonin) and arterial blood gas analysis (partial pressure of oxygen/fraction of inspired oxygen [pO2/FiO2] ratio, oxygen saturation), were recorded at hospital admission and immediately before or soon after oxygen supplementation, concomitantly with the blood sampling needed for the analysis described in the following text. Data from 46 HS (35% male, mean age 42 ± 11 years) and 46 stable coronary artery disease (CAD) patients (91% male, mean age 67 ± 10 years) with recent (<6 months) percutaneous coronary revascularization, and on dual antiplatelet therapy, previously recruited at Centro Cardiologico Monzino IRCCS, Milan, were analyzed for comparisons. The study was approved by the Ethical Committee of the Institution (number 2020_06_16_18), and informed consent was obtained from all participants according to the principles of the declaration of Helsinki.

**STATISTICAL ANALYSIS.** Quantitative variables are presented as median with 25th and 75th percentiles, being mostly log-normally distributed; within-group comparisons were made with the Wilcoxon signed rank test, and between-group comparisons were made with the Wilcoxon rank sum test. The normality of the variable distributions was assessed by the use of the D’Agostino-Pearson omnibus K2 test. Categorical variables are presented as n (%) and were compared by chi-square or Fisher’s exact test, when appropriate. Associations between variables were assessed by Spearman’s correlation coefficient (rs). A p value <0.050 was considered statistically significant. p Values presented in this report have not been adjusted for multiplicity to protect type I error, and
therefore, the reproducibility (statistical power) of the inferences drawn from these statistics could be questioned. All analyses were performed using GraphPad Prism version 9.0 software (GraphPad Software, San Diego, California) and SAS version 9.4 software (SAS Institute, Cary, North Carolina).

See the Supplemental Appendix for extended experimental procedures.

| TABLE 1 | Demographic and Clinical Characteristics of Enrolled COVID-19 Patients |
|----------|---------------------------------------------------------------|
|          | All (N = 46) | Oxygen Therapy [Group 1] (n = 20) | Mechanical Ventilation [Group 2] (n = 26) | p Value |
| Age, yrs | 72 (58-84) | 67 (58-81) | 74 (63-84) | 0.288 |
| Male     | 28 (61)   | 11 (55)   | 17 (65)    | 0.182 |
| In-hospital mortality | 10 (21.7) | 0 (0) | 10 (38.5) | 0.031 |
| Length of hospitalization, days | 40.5 (29-43.5) | 40 (29-47) | 41 (29-43) | 0.862 |
| Interleukin-6, pg/ml | 41 (27-77) | 32 (24-37) | 70 (39-107) | 0.028 |
| CRP, mg/dl | 8.8 (4.6-12.3) | 4.7 (1.5-7.4) | 11.8 (7.1-17.1) | <0.001 |
| D-dimer, mg/l | 2,122 (774-2,139) | 1,229 (774-1,727) | 1,612 (981-2,787) | 0.192 |
| Arterial gas analysis | | | | |
| Oxygen saturation | 94.5 (92-97) | 96 (93-97) | 94 (88-97) | 0.149 |
| Respiratory rate | 20 (18-24) | 18 (18-20) | 22 (18-27) | 0.035 |
| pCO₂ | 36.5 (33-44) | 36.5 (35-39.5) | 37.5 (32-44) | 0.871 |
| pO₂/FiO₂ ratio | 177 (132-343) | 362 (324-397) | 160 (130-180) | 0.002 |
| pH | 7.5 (7.4-7.5) | 7.5 (7.5-7.5) | 7.5 (7.4-7.5) | 0.269 |
| Lactate | 1.3 (0.9-1.6) | 1.4 (0.7-1.5) | 1.3 (1-1.7) | 0.478 |
| Cardiovascular risk factors | | | | |
| Smoking status | | | | |
| Active smoker | 3 (8) | 2 (10) | 1 (4) | 0.577 |
| Former smoker | 6 (16) | 3 (15) | 3 (11) | |
| Dyslipidemia | 2 (5) | 0 (0) | 2 (8) | 0.979 |
| Hypertension | 32 (69) | 13 (65) | 19 (73) | 0.348 |
| Diabetes | 4 (11) | 0 (0) | 4 (18) | 0.138 |
| Past medical history | | | | |
| Cardiovascular diseases | 33 (87) | 13 (65) | 20 (77) | 0.979 |
| Cerebrovascular diseases | 7 (18) | 2 (10) | 5 (8) | 0.681 |
| Respiratory diseases | 10 (27) | 4 (20) | 6 (23) | 0.968 |
| Endocrinologic diseases | 8 (21) | 3 (15) | 5 (22) | 0.897 |
| Renal diseases | 2 (5) | 0 (0) | 2 (8) | 0.240 |
| Pharmacological therapy | | | | |
| LMWH treatment, dose | 36 (80) | 22 (88) | 14 (70) | 0.161 |
| 4,000 U | 1 (2.2) | 1 (4) | 0 (0) | 0.623 |
| 6,000 U | 5 (11.1) | 3 (12) | 2 (10) | |
| 4,000 U × 2 | 17 (37.8) | 10 (40) | 7 (35) | |
| 6,000 U × 2 | 11 (24.4) | 6 (24) | 5 (25) | |
| 8,000 U × 2 | 2 (4.4) | 2 (8) | 0 (0) | |
| Antiplatelet agents | 5 (11) | 5 (25) | 0 (0) | <0.001 |
| Hydroxychloroquine | 4 (12) | 3 (15) | 1 (4) | 0.087 |
| Cortisone | 13 (30) | 4 (20) | 9 (34) | 0.922 |
| Biochemical parameters | | | | |
| Ferritin, μg/l | 857 (498-1,686) | 498 (358-1,758) | 946 (612-1,365) | 0.634 |
| AST, U/l | 35 (23-44) | 30 (18-40) | 38 (29-46) | 0.314 |
| ALT, U/l | 30 (20-57) | 24 (16-33) | 31 (23-65) | 0.117 |
| LDH, U/l | 326 (249-383) | 256 (181-314) | 348 (317-390) | 0.027 |
| S-Creatinine, mg/dl | 0.9 (0.7-1.0) | 0.8 (0.6-0.9) | 0.9 (0.8-1.1) | 0.016 |
| PT/INR | 1.22 (1.15-1.30) | 1.25 (1.13-1.34) | 1.19 (1.15-1.24) | 0.938 |
| PTT ratio | 1.35 (1.18-1.47) | 1.39 (1.19-1.56) | 1.33 (1.18-1.44) | 0.152 |
| TnT, ng/l | 26 (13-48) | 26 (17-37) | 26 (11-49) | 0.700 |
| ProBNP, ng/l | 197 (97-315) | 159 (60-207) | 315 (172-521) | 0.059 |
| Procalcitonin, ng/ml | 0.1 (0.1-0.2) | 0.1 (0-0.1) | 0.2 (0.1-0.3) | 0.118 |
| Fibrinogen, mg/dl | 546 (412-637) | 424 (379-627) | 546 (474-647) | 0.302 |

Continued on the next page
RESULTS

PATIENT CHARACTERISTICS. Baseline characteristics of the enrolled patients are summarized in Table 1. The median age was 67 [58 to 81] years and 74 [63 to 84] years, for patients on oxygen therapy (group 1) and invasive or noninvasive mechanical ventilation (group 2), respectively, with a predominance of men in both groups (55% and 65% in group 1 and group 2, respectively). Chronic diseases, including cardiovascular and cerebrovascular, respiratory system, endocrinologic, and kidney diseases were comparable between the 2 groups. In the patients requiring mechanical ventilation, the arterial blood gas analysis parameters, in particular the pO2/FiO2 ratio, were significantly worse. Ferritin, LDH, serum creatinine, procalcitonin, D-dimer, fibrinogen, CRP, and IL-6, measured at hospital admission, were higher in group 2 patients. At the time of blood sampling for the analysis described in the following text, group 2 patients also had lower platelet, lymphocyte, and monocyte counts, and lower hemoglobin levels. Conversely, the platelet-related parameters platelet distribution width, mean platelet volume, platelet large cell ratio, and immature platelet fraction were all significantly greater compared with group 1. During hospitalization, LMWH at prophylactic (1 per day) or therapeutic (2 per day) regimen, hydroxychloroquine and corticosteroid treatment was comparable between the 2 groups, whereas antiplatelet drugs were administered in only 5 group 1 patients (25%). No symptomatic venous thromboembolisms were diagnosed during hospitalization.

CHARACTERIZATION OF TF-EXPRESSING CELLS AND MVs. We first assessed TF expression among the circulating cells and MVs. Whole-blood flow cytometry analysis of TF+ cells showed that the median level of TF+ platelets in COVID-19 patients was significantly higher than that found in HS (p = 0.007), with a trend toward greater values in group 2 (Figures 1A and 1B). Interestingly, 40% of patients in group 1 had TF+ platelets far above the median value of HS.

Granulocytes were also ~3-fold greater in COVID-19 compared with HS (p < 0.001) (Figure 1C), whereas only a trend increase was observed for TF+ monocytes (Figure 1D). Distribution of TF+ granulocytes and monocytes was not different between COVID-19 patients. Notably, TF+ platelets and granulocytes were also significantly higher in COVID-19 than in CAD patients on dual antiplatelet therapy, whereas TF+ monocytes were similar (Supplemental Figure 1).

MVs were assessed in plasma, taking into account: 1) their total number; 2) the procoagulant phenotype in terms of annexinV (AnnV) binding to PS and TF expression; and 3) their cell origin, focusing on those derived from platelets, granulocytes, monocytes, erythrocytes, and endothelium. Total and TF+ MVs were significantly higher in COVID-19 patients compared with HS, whereas the AnnV+ MVs were lower (Table 2). All the parental cells released a double amount of TF+ MVs, the most abundant coming...
from platelets and erythrocytes, followed by those from endothelium, granulocytes, and monocytes. Despite a similar MV distribution in the 2 COVID-19 groups, the number of procoagulant MVs (AnnV+/TF+) was greater in group 2 patients (Supplemental Figure 2). Notably, almost all the TF+ MVs were significantly higher in COVID-19 than in CAD patients (Supplemental Table 1).

Considering the massive expression of cell- and MV-associated TF measured, we then tested the residual plasma thrombin generation capacity. At the time of our sampling, all but 20% of patients were on LMWH (Table 1). When no exogenous TF was used to trigger the reaction, the few patients that were not on LMWH generated thrombin much faster than HS (lag time 11.3 [10 to 22.3] min and 23.3 [18.7 to 30.2] min, respectively). Among those on LMWH, thrombin generation was observed in 20% of patients. The time needed for thrombin formation was as high as that of HS (lag time 21 [18.3 to 22] min and 23.3 [18.7 to 30.2] min in COVID-19 patients and HS, respectively) and they accounted for 30% of those treated with prophylactic LMWH.

When the TF-FVIIa complex formation was no longer the limiting step in the system (by adding excess of exogenous TF), residual thrombin formation was observed in all patients treated with 6,000 U/day and in 40% of those with 8,000 to 16,000 U/day LMWH, being mainly (70%) in group 2.

In addition, despite the administration of comparable daily-dose LMWH, thrombin was more than 3- to 5-fold higher in group 2 than in group 1 patients (endogenous thrombin potential [ETP] 1,064 [1,040 to 1,240] nmol/l × min vs. 584 [529 to 638] nmol/l × min, respectively; p < 0.001; peak high 165 [156 to 169] nmol/l vs. 40.7 [35 to 46.4] nmol/l thrombin, respectively; p < 0.001), evidencing a higher prothrombotic risk in patients with reduced respiratory capacity. Interestingly, the ETP correlated with the number of procoagulant MVs (r = 0.495; p = 0.020).

Overall these data, underscoring the marked prothrombotic phenotype associated with both TF-bearing cells and MVs, provide insights into the potential mechanisms that trigger the hypercoagulable state, especially in severe COVID-19 patients.
CHARACTERIZATION OF PLATELET ACTIVATION.
Platelet-associated TF expression and circulating platelet-derived MVs are only 2 among the markers of platelet activation. For a more comprehensive analysis, we also assessed P-selectin exposure and platelet-leukocyte aggregate (PLA) formation. The percentage of P-selectin$^+$ platelets was 10-fold higher in COVID-19 patients compared with HS ($p = 0.006$) (Figure 2A). This was paralleled by a marked increase in the frequencies of granulocyte-platelet aggregates (GPA) and monocyte-platelet aggregates (MPA; $p < 0.001$) (Figures 2B and 2E), as well as in TF$^+$ aggregates ($p < 0.001$) (Figures 2D and 2F). All these parameters were also higher compared with CAD patients (Supplemental Figure 3). Of note, IL-6, CRP, and D-dimer levels negatively correlated with GPA ($r = -0.38; p = 0.022; r = -0.45; p = 0.002,$ and $r = -0.47; p = 0.003,$ respectively) and MPA ($r = -0.51; p = 0.002; r = -0.53; p < 0.001,$ and $r = -0.35; p = 0.033,$ respectively). Indeed, GPA and MPA were significantly lower in group 2 than in group 1 ($p = 0.003$ and $p = 0.004,$ respectively) (Figures 2C and 2F).

All together, these results sustain the concept of a very high platelet activation state in COVID-19 patients. Moreover, the negative correlation of PLA with inflammatory and thrombotic parameters, along with the lower platelet count of group 2 patients, suggests their possible consumption even in COVID-19 patients considered to be at low risk.

CHARACTERIZATION OF ENDOTHELIAL ACTIVATION.
Perturbed endothelium, as occurs during systemic infection, affects platelet activation ($7$). Thus, we evaluated the extent of endothelial dysfunction by assessing NO and PGI$_2$ production. COVID-19 patients showed an impairment in NO biosynthetic pathway, being almost one-half the concentration of arginine and twice the levels of asymmetric dimethylarginine (ADMA), the specific NO synthase inhibitor, compared with HS ($p < 0.001$) (Figures 3A and 3B). Global arginine bioavailability ratio, calculated as arginine/(ornithine+citrulline), was significantly reduced in COVID-19 patients as a result of the higher levels of ornithine compared with HS (Figures 3C and 3D). Similar data were observed comparing COVID-19 to CAD patients (Supplemental Figure 4). Of note, ornithine concentrations were also significantly lower in group 2 compared with group 1 patients ($p = 0.048$) (Figure 3E), and citrulline, which is produced in equimolar amounts to NO, behaved similarly (Figures 3F and 3G). COVID-19 patients also had higher concentrations of 6-ketoprostaglandin F$_1$ alpha (6ketoPGF$_{alpha}$), the main plasma metabolite of COX-2-produced PGI$_2$, than those of HS ($p = 0.010$) (Figure 3H) with higher levels in group 2 compared with group 1 patients ($p = 0.035$) (Figure 3I).

The relation between l-arginine/NO pathway impairment and the systemic inflammatory response was supported by the negative correlation between CRP and both arginine and citrulline ($r = -0.34; p = 0.037; r = -0.42; p = 0.009,$ respectively) and IL-6 with both citrulline and ornithine ($r = -0.45; p = 0.014; r = -0.43; p = 0.012,$ respectively).

Taken together, these data highlight the endothelial impairment that could affect platelet activation.

IN VITRO MODEL OF COVID-19-INDUCED PLATELET ACTIVATION. In consideration of the relevance of the cytokine storm in the pathogenesis of severe COVID-19, we tested whether the cytokine content of plasma from COVID-19 patients reproduced, in cells from HS, the massive platelet activation observed in vivo. Blood from HS was plasma-depleted and reconstituted with plasma pools from COVID-19 patients or from HS. Analysis performed after 30-min incubation showed that only COVID-19 plasma significantly increased the number of TF$^+$ platelets (Figure 4A) and their TF-dependent thrombin generation capacity (lag time 13.4 [13.2 to 14.1] min and 15.7 [14.8 to 16.4] min for COVID-19 and HS plasma, respectively; $p < 0.002$) (Supplemental Figure 5C).

Plasma COVID-19 also induced MV release, as well as expression of the other platelet activation markers (Figures 4B to 4G), but activated glycoprotein (GP) IIB/IIIa and PS exposure (Supplemental Figures 5A and 5B). Interestingly, this activation was not due to a direct effect of SARS-CoV-2 because digital PCR...
analysis ruled out its presence in patients’ plasma (Supplemental Figure 6).

Among the mediators released during the cytokine storm, IL-6 seems to play a major role because efficacy of anti–IL-6R blockade with tocilizumab has been reported (13). Thus, we explored whether IL-6 added to blood from HS could recapitulate the effect observed with COVID-19 plasma. Interestingly, IL-6, at concentrations comparable to those found in COVID-19 patients, was ineffective in inducing cell activation. Conversely, it significantly potentiated the effect of low-concentration adenosine diphosphate (ADP) or thromboxane A2 (stable analogue U46619), endogenous platelet agonists released on activation, resulting in cell stimulation resembling that observed with COVID-19 plasma for all the parameters assessed (Figure 4, Supplemental Figure 7).

On the basis of these findings, we then assessed the effect of blocking IL-6 signaling. To this aim, plasma COVID-19 and blood from HS were treated with tocilizumab at 2 concentrations close to those achieved in therapy. The drug concentration dependently blunted the effect of COVID-19 plasma on the expression of TF⁺ platelets, TF⁺ aggregates, and TF⁺-platelet-derived MVs (Figures 5A, 5F, 5H, and 5I) and significantly reduced platelet-associated thrombin generation (Figures 5B and 5C), P-selectin expression (Figure 5D), and GPA, and MPA formation (Figures 5E and 5G).
FIGURE 3  Evaluation of Endothelial Activation Markers in COVID-19 Patients and HS

Plasma levels of L-arginine (Arg) (A), asymmetric dimethylarginine (ADMA) (B), global arginine bioavailability ratio (GABR) (C), L-ornithine (Orn) (D), L-citrulline (Cit) (F), and 6-keto-PGF₁α (H). L-ornithine (E), L-citrulline (G), and 6-keto-PGF₁α (I) in group 1 and group 2 COVID-19 patients. Abbreviations as in Figure 1.
Overall, results obtained with this approach suggest that the platelet activation observed in COVID-19 patients is not directly caused by SARS-CoV-2. Furthermore, these data support the clinical evidence pointing toward a key role of IL-6 in the coagulopathy described in severe COVID-19 patients.

IN VITRO MODULATION OF COVID-19-INDUCED PLATELET ACTIVATION BY ANTIPLATELET DRUGS. Finally, because in vitro data confirm the sustained platelet activation documented in vivo, we evaluated whether aspirin and the P2Y₁₂ inhibitor AR-C69931MX
Plasma-depleted blood from HS (n = 5) has been reconstituted with COVID-19 plasma pool (orange bars) or COVID-19 plasma pool pre-incubated with tocilizumab (Toc; 100 or 300 μg/ml; blue and light blue bars, respectively) or with an irrelevant (Irrel) IgG (300 μg/ml; grey bars). Blood reconstituted with autologous plasma is reported for comparison (white bars). Percentage of TF⁺ and P-selectin⁺ platelets (A and D), CD41⁺ TF⁺ MVs (I), total and TF⁺ granulocyte-platelet aggregates (E and F) and monocyte-platelet aggregates (G and H). (B) Time needed for platelet-associated thrombin generation (TG) (lag time). (C) Representative curves of TG were reported. Abbreviations as in Figures 1 and 2.
prevented it. Both antiplatelet agents significantly inhibit COVID-19 plasma-induced platelet activation and MV release, AR-C69931MX being more effective than aspirin in reducing TF$^+$ platelets and TF$^+$-platelet-derived MVs, as well as P-selectin. Association of these drugs did not result in any additive effect (Figure 6). These data suggest the potential benefit of antiplatelet agents in the management of the thrombotic complication of COVID-19 patients.
Viral infections, bacterial infections, and inflammatory stimuli are well-known inducers of TF expression in endothelial cells, monocytes, and granulocytes (4,15). By adding an ex vivo and in vitro approach to the snapshot of the in vivo situation, this study clearly highlights how platelet TF is also fundamental in the thromboinflammation triggered by SARS-CoV-2. Even numbers come in handy in pathophysiology: when the absolute number of TF+ events is computed, taking into account the blood cell concentration, the number of circulating TF+ platelets is ~100 times higher than that of granulocytes.

Although the research on TF modulation in platelets is relatively more recent than that on endothelium and leukocytes, several studies have documented by now that, upon platelet activation by the common agonists, TF translocates from the cytoplasm to the cell membrane where it can trigger thrombin generation (9,16,17). More recently, we have shown that also angiotensin II (ATII) stimulates platelets to express TF (18). This mechanism may have direct implications in COVID-19 coagulopathy where ATII levels increase as a result of the down-regulation of angiotensin-converting enzyme 2 (ACE2), the main host cell receptor of SARS-CoV-2, following virus binding (19). In view of the cytokine storm present in COVID-19 patients, the finding that TNFα elicited platelet activation and TF expression, which in turn prompted thrombin generation and clot formation, has also to be considered (15). Interestingly, it has been previously reported that HIV-infected patients, who have an increased risk for thrombotic and cardiovascular events, also have significantly higher levels of TF+ platelets and P-selectin+ platelets and MVs compared with noninfected subjects (20). Furthermore, in these patients, the risk of death, including that due to cardiovascular events, was linked to higher plasma levels of IL-6, CRP, and D-dimer, similar to what observed in COVID-19 (21).

In these patients, we also observed a very strong up-regulation of platelet P-selectin (10-fold higher than HS). Platelets amplify TF expression on leukocytes via the interaction of P-selectin with PSGL-1, its counter-receptor on monocytes and neutrophils (22). Moreover, P-selectin plays a key role also in the formation of PLA, important elements for the regulation of the immune response and the clearance of infectious agents. By binding and activating leukocytes, platelets promote their effector functions. Platelet-neutrophil complexes have more activated adhesion molecules, greater phagocytic ability, and greater toxic oxygen metabolites than noncomplexed
COVID-19: Platelet and Endothelial Activation

Canzano et al.

The experimental ex vivo/in vitro approach offers several considerations. First, the massive platelet activation observed in COVID-19 patients is not a direct effect of the virus because SARS-CoV-2 has been detected in blood in a low percentage of infected patients and at very low levels, and no documented cases of transfusion transmission have been reported in the published reports. Conversely, platelet activation is consistent among all patients in this study; and ACE2 is mainly expressed in the lung, intestine, kidney, and blood vessels (31). No evidence for its presence in platelets has been reported so far; SARS-CoV-2 was not detected in the COVID-19 plasma pools used to test their effects on platelets of healthy subjects in vitro. In this setting, platelets are readily activated, and the effect of plasma, especially on TF expression, is blunted by tocilizumab, pointing to IL-6 as 1 of the mediators involved. Second, in COVID-19 patients, platelets are likely pre-activated due to the endothelial dysfunction and the lack of NO bioavailability. In this scenario, the presence of IL-6 within the cytokine storm enhances the effect of mediators released by the activated platelet. This finding is supported by the fact that IL-6 alone does not activate platelets in vitro, but it potentiates the effect of ADP or TxB2. These data are consistent with a previous study that showed how IL-6 trans-signaling has no effect on platelet degranulation and aggregation by itself (32). Second, aspirin and P2Y12 inhibitors prevent platelet activation induced by COVID-19 plasma. Indeed, aspirin and P2Y12 inhibitors have been previously shown to be able to reduce heterotypic PLA, with the effect of the P2Y12 inhibitors being more potent and consistent, throughout the studies, compared with that of aspirin (33). Moreover, inhibition of P2Y12, not only blocks ADP, but also affects the release of sIL-6R, the specific soluble receptor needed for IL-6 signaling through the membrane-bound gp130 (32). Interestingly, Viecca et al. (34) recently showed that the combined use of several antiplatelet therapies in severe COVID-19 patients with a thrombophilic profile resulted in improved gas exchange efficiency and increased arterial oxygenation. Third, the platelet activation documented in COVID-19 patients has a peculiar feature to fight the virus. The strong induction of TF and P-selectin expression, and PLA formation was observed in the absence of GPIIb/IIIa activation, lacking, therefore, the condition sine qua non to form platelet-platelet aggregates and confer a thrombotic risk. It is conceivable, however, that when the balance between the mechanisms that drive a robust antiviral immune response and regulators that function to limit an excessive immune response are lost, an overt immune-mediated pathology takes over. Thus, although our data should be confirmed in a larger study population, they provide...
the scientific rationale to support the ongoing interventional clinical trials aiming at assessing whether the use of well-known antiplatelet agents ACTCOVID19 (Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial NCT04324463); C-19-ACS [Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial]; NCT04333407; COVID-PACT [Prevention of Arteriovenous Thrombotic Events in Critically-III COVID-19 Patients Trial]; NCT04409834; CORONA [Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA STUDY)]; NCT04518735) or COVACTA [IL-6R antagonists (A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia]; NCT04320615; FMTVDM [The Fleming (fFMTVDM)) Directed CoVid-19 Treatment Protocol; NCT04349410; COVIDOSE-2 [Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19]; NCT04479358; ARCHITECTS [Trial of Tocilizumab for Treatment of Severe COVID-19]; NCT04412772] may blunt the coagulopathy occurring in COVID-19 patients, with the ultimate goal to markedly improve their overall prognosis. This intriguing hypothesis is further supported by the finding that severe COVID-19 patients may develop pulmonary embolism/small local thrombi despite prophylactic and even empiric treatment-dose anticoagulation (14), suggesting that an other antithrombotic therapy may be necessary for this therapeutic goal.

**STUDY LIMITATIONS.** Our findings should be interpreted in the context of their limitations. First, data on the cell activation status found in COVID-19 patients are based on a small sample size. Nevertheless the results appear consistent and are further corroborated by the in vitro data. Furthermore, it is worth mentioning that, considering the emergency status existing at the time of patient enrollment and blood withdrawal, and the need to handle blood samples according to more stringent safety procedures, a great effort has been made to carry out such a thorough analysis. Second, our data suggest that an elevated baseline hemostatic potential, despite the anticoagulant treatment, could be responsible for the high thrombotic risk of COVID-19 patients; however, we cannot exclude a potential role of heparin resistance (35) in the high hypercoagulable state of COVID-19 patients. Likewise, we cannot rule out an off-target effect of LMWH on platelet activation; however, the 2 groups of patients were similarly treated even after adjustment for LMWH U/kg. Third, no systematic search for venous thromboembolic events was performed in our study population, given the risk of transmitting the infection to health care personnel and admitted patients. Thus, future studies should confirm our findings and assess whether they do correlate with the clinical and imaging observation of symptomatic or asymptomatic thromboembolic events. Fourth, due to the small sample size, no correlation of cell-activation parameters with clinical outcome(s) has been performed.

**CONCLUSIONS.** All together our findings revealed how the cytokine storm present in COVID-19 patients induces, in concert with the imbalance of the endothelial functions, a massive cell activation with production of TF, mainly by platelets, granulocytes, and MVs, these latter responsible for the residual thrombin generation capacity measured in plasma of all patients treated with prophylactic anticoagulation. Furthermore, COVID-19 patients are characterized by a sustained platelet activation with formation of PLA that may be involved in the microthrombi found in autopic specimens. Finally, these results provide insights into the IL-6-mediated platelet activation that triggers the hypercoagulable state in COVID-19, suggesting the potential effectiveness of anti-IL-6 antibodies and antiplatelet drugs.

**AUTHOR DISCLOSURES.** This work was supported by a grant from Italian Ministry of Health (Ricerca Corrente Reti 2020- RCR-2020-2367065, to Prof. Camera). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**ADDRESS FOR CORRESPONDENCE:** Prof. Marina Camera, Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Balzaretti, 9, 20133 Milan, Italy. E-mail: Marina.Camera@unimi.it; OR Centro Cardiologico Monzino IRCCS, Via Parea 4, 20138 Milan, Italy. E-mail: Marina.Camera@ccfm.it.
1. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18:1421-4.

2. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191:9-14.

3. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation in patients with severe COVID-19 pneumonia. J Thromb Haemost 2020;18:844-7.

4. van Gorp EC, Suharti C, ten Cate H, et al. Reperfusion events in COVID-19 patients in Brescia, Italy. Autoimmun Rev 2020;19:102568.

5. Mackow ER, Gorbunova EE, Gavrilovskaya IN. –80. PERSPECTIVES

6. Golshiri K, Ataei Ataabadi E, Portilla van Gorp EC, Suharti C, ten Cate H, et al. Reperfusion events in COVID-19 patients in Brescia, Italy. Autoimmun Rev 2020;19:102568.

7. Mehta P, McAuley DF, Brown M, et al. COVID-19. Lancet 2020;395:1033-4.

8. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2:e474-84.

9. Toniati P, Piva S, Cattalin M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19:102568.

10. Issa N, Durney M, Guisset D, Mourissoux G, Bonnet F, Camou F. Feasibility of tocilizumab in ICU patients with COVID-19. J Med Virol 2021;93:46-7.

11. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2950-73.

12. Manfredi AA, Baldivis M, Camera M, et al. Anti-TNFalpha agents curb platelet activation in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1511-20.

13. Camera M, Frigerio M, Toschi V, et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antplatelet drugs. Arterioscler Thromb Vasc Biol 2003;23:1690-6.

14. Camera M, Brambilla M, Toschi V, Tremoli E. Tissue factor expression on platelets is a dynamic event. Blood 2010;116:5076-7.

15. Camera M, Gelosa P, Rossetti L, et al. Impact of angiotensin-converting enzyme inhibition on platelet tissue factor expression in stroke-prone rats. J Hypertens 2018;36:1360-71.

16. Malha L, Mueller FB, Pecker MS, Mann SJ, August P, Feig PU. COVID-19 and the renin-angiotensin system. Kidney Int Rep 2020;5:563-56.

17. Mayne E, Funderburg NT, Sieg SF, et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr 2012;59:340-6.

18. August P, Feig PU. COVID-19 and the renin-angiotensin system. Kidney Int Rep 2020;5:563-56.

19. Fischer G, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984;310:1065-8.
31. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631–7.

32. Marino M, Scuderi F, Ponte E, et al. Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets. J Biol Regul Homeost Agents 2013;27:841–52.

33. Schrottmaier WC, Kral JB, Badmya S, Assinger A. Aspirin and P2Y12 inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost 2015;114:478–89.

34. Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res 2020;158:104950.

35. White D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis 2020;50:287–91.

KEY WORDS antiplatelet drugs, circulating microvesicles, COVID-19, IL-6, platelet activation, tissue factor

APPENDIX For an expanded Methods section as well as supplemental figures and table, please see the online version of this paper.